Every 10-Q that Intelligent Bio Solutions Inc. (INBS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INBS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBS filings page.
Intelligent Bio Solutions Inc. reported strong revenue growth but continued losses for the quarter and nine months ended March 31, 2026. Revenue rose to $1.06 million for the quarter and $3.07 million for nine months, representing approximately 46% and 39% increases over the prior-year periods, driven by new customers and higher cartridge reorders. Gross margin improved to about 50% for the quarter and 49% for nine months as volumes and product mix shifted toward higher-margin consumables.
Despite this, the company posted a nine‑month net loss of $8.55 million and used $8.74 million of cash in operating activities. Cash and cash equivalents were $6.86 million as of March 31, 2026, with shareholders’ equity of $8.75 million. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next 12 months without additional financing and expects ongoing operating losses.
To support liquidity, the company raised capital through an at‑the‑market program and warrant exercises, and completed a December 2025 private placement with gross proceeds of about $10.0 million. Common shares outstanding increased to 2,391,846 as of May 12, 2026, reflecting significant equity issuance.
Intelligent Bio Solutions Inc. reported higher revenue but continued losses for the quarter ended December 31, 2025. Revenue rose to $896,774 from $607,494 a year earlier, driven by new customers and stronger cartridge reorders, with gross margin improving to 48.69%.
Despite this growth, the company recorded a quarterly net loss attributable to Intelligent Bio Solutions of $2,677,590 and a six‑month net loss of $5,660,596. Cash and cash equivalents were $740,371 at December 31, 2025, plus a shareholder subscription receivable of $9,402,105 that was collected on January 2, 2026.
Shareholders’ equity increased to $10,889,811, supported by at‑the‑market share sales, warrant exercises, and a $10.0 million December 2025 private placement. However, management states that expected operating losses and limited cash resources raise substantial doubt about the company’s ability to continue as a going concern without additional financing.
Intelligent Bio Solutions Inc. (INBS) reported results for the quarter ended September 30, 2025. Revenue was $1,111,797, up from $872,287, with gross profit of $518,291 and an improved gross margin of 46.6%. Government support income was $193,267. Operating expenses rose to $3,711,151, including $2,659,824 in SG&A, $486,169 in development and regulatory costs, and a $261,780 impairment.
The company recorded a net loss of $2,994,992 (loss per share $0.35). Cash and cash equivalents were $1,660,105, with a working capital deficit of $577,705. Management stated that these conditions raise substantial doubt about the company’s ability to continue as a going concern without additional funding.
INBS raised funds via equity: $3,332,646 net from July 2025 warrant inducements and $213,750 net through its ATM program during the quarter. Warrants outstanding totaled 7,935,928. As of November 10, 2025, 9,452,553 common shares were outstanding. Management reported material weaknesses in internal control over financial reporting and disclosed Nasdaq minimum bid price compliance risk.